Table 2 Comparison of clinical and analytical characteristics of children with early versus late diagnosis

Opportunistic infections during follow-up

8/20 (40%)

17/44 (38.64%)

0.9

Clinical stage N/A during follow-up

5/19 (26.32%)

16/38 (42.11%)

0.38

Clinical stage C during follow-up

12/19 (63.16%)

24/45 (53.33%)

0.47

Immunological stage 3 throughout follow-up

6/17 (35.29%)

9/32 (28.13%)

0.6

Pathological psychomotor development during follow-up

6/20 (30%)

7/40 (17.5%)

0.27

CD4 cells at check-up 4 (cells/µl)

Median (IQR), n = 56

1175 (770)

1050 (477)

0.08

CD4 percentage at check-up 4

Median (IQR), n = 36

35.7% (9.70%)

33% (10.25%)

0.4

CD4/CD8 ratio at check-up 4

Median (IQR), n = 26

1.14 (0.84)

0.84 (0.56)

0.5

Viral load at check-up 4 (copies/ml)

Median (IQR), n = 59

40 (186)

20 (45)

0.09

Good adherence at all check-ups

10/20 (50%)

32/41 (78.04%)

0.03

Toxicity during follow-up

1/20 (5%)

8/41 (19.51%)

0.13

Psychosocial care during follow-up

20/22 (90.91%)

44/49 (89.80%)

1

Hospitalization during follow-up

8/21 (38.10%)

9/40 (22.50%)

0.2

Deaths during follow-up

0/20 (0%)

3/43 (6.98%)

0.55